Unraveling the role of HDAC3 as an immunotherapy prognostic biomarker and therapeutic target in advanced non-small cell lung cancer
Abstract Background This study investigates HDAC3 as a potential immunotherapy biomarker in advanced non-small cell lung cancer (aNSCLC), focusing on its association with treatment response to immune checkpoint inhibitors (ICIs). Methods We employed a multi-phase approach in 78 aNSCLC patients with...
Saved in:
| Main Authors: | Liyuan Dai, Liling Huang, Lin Li, Le Tang, Yuankai Shi, Xiaohong Han |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-06-01
|
| Series: | Respiratory Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12931-025-03275-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Multi-omics unveils BCAA metabolism markers L-leucine and HMGCS1 as prognostic marker for immunotherapy efficacy in non-small cell lung cancer
by: Liyuan Dai, et al.
Published: (2025-06-01) -
HDAC3: A Multifaceted Modulator in Immunotherapy Sensitization
by: Rui Han, et al.
Published: (2025-02-01) -
Immunotherapy of small cell lung cancer based on prognostic nutritional index
by: Xinling Zhang, et al.
Published: (2025-05-01) -
Histone Deacetylase (HDAC) Inhibitors as a Novel Therapeutic Option Against Fibrotic and Inflammatory Diseases
by: Maria A. Theodoropoulou, et al.
Published: (2024-12-01) -
HDAC1 Mediates Immunosuppression of the Tumor Microenvironment in Non-Small Cell Lung Cancer
by: Fan Y, et al.
Published: (2025-03-01)